Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting.
Anti-IL12/23 antibodies
Anti-IL17 antibodies
Anti-TNFα antibodies
Psoriatic arthritis
Retention rate
bDMARDs
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
02
09
2019
accepted:
05
03
2020
revised:
12
02
2020
pubmed:
20
3
2020
medline:
15
5
2021
entrez:
20
3
2020
Statut:
ppublish
Résumé
Biologic disease-modifying antirheumatic drugs (bDMARDs) play a pivotal role in the treatment of psoriatic arthritis (PsA). Despite this, their discontinuation due to inefficacy or adverse events is often observed. The aims of this study are to describe retention rates and treatment trends of anti-TNFα, anti-IL17, and anti-IL12/23R agents in patients with PsA and to identify factors associated with bDMARDs discontinuation in a real-world clinical setting. A retrospective cohort study based on the analysis of the three Italian prescription cohorts of patients with PsA has been performed. Survival analysis was performed using Kaplan-Meier curves and Cox proportional-hazards model. During the follow up, which lasted 25.5 (12-60) months, 68 patients discontinued a bDMARD: 13 for primary failure, 12 for secondary failure, 15 for adverse events, 5 for remission, 12 because of lost at follow-up, and 11 for other causes. Cox proportional-hazards demonstrated that a shorter disease duration (HR 0.994991, 95% CI 0.9910336-0.9989647, p = 0.014) and first-line bDMARD (HR 0.5090986, 95% CI 0.3073519-0.8432722, p = 0.009) have a protective role on bDMARD retention rate, while the multivariable analysis failed in demonstrating an independent protective role of male sex on drug retention rate (p = 0.083). No significant differences in retention rate have been found regarding biologic drugs, combination therapy or monotherapy, and class of bDMARD (anti-TNFα or anti-pIL12/23R and anti-IL-17). This study shows that a shorter disease duration and treatment with a first-line bDMARD are predictors of bDMARDs retention rate, further highlighting the importance of early diagnosis of PsA. Key Points • No significant difference in retention among patients treated with anti-IL17A, anti-IL12/23R, and anti-TNFα agents has been demonstrated. • A shorter disease duration and first-line bDMARD treatment are associated with persistence in biologic treatment.
Identifiants
pubmed: 32189149
doi: 10.1007/s10067-020-05027-1
pii: 10.1007/s10067-020-05027-1
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2663-2670Références
Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D'Angelo S, Mathieu A, Cauli A, Punzi L, Ramonda R, Scarpa R, Maccarone M, Lubrano E (2017) Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol 35(6):991–1010
pubmed: 29185959
Napolitano M, Caso F, Scarpa R, Megna M, Patri A, Balato N, Costa L (2016) Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol 35(8):1893–1901. https://doi.org/10.1007/s10067-016-3295-9
doi: 10.1007/s10067-016-3295-9
pubmed: 27156076
Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. SpringerPlus 3:759. https://doi.org/10.1186/2193-1801-3-759
doi: 10.1186/2193-1801-3-759
pubmed: 25674484
pmcid: 4320171
Caso F, Costa L, Del Puente A, Di Minno MN, Lupoli G, Scarpa R, Peluso R (2015) Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Ther Adv Chronic Dis 6(6):328–338. https://doi.org/10.1177/2040622315608647
doi: 10.1177/2040622315608647
pubmed: 26568809
pmcid: 4622317
Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L, Balato N, Scarpa R (2018) Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol 37(7):1739–1741. https://doi.org/10.1007/s10067-018-4090-6
doi: 10.1007/s10067-018-4090-6
pubmed: 29644570
Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12(3):315–331. https://doi.org/10.1586/1744666x.2016.1117941
doi: 10.1586/1744666x.2016.1117941
pubmed: 26558483
Caso F, Costa L, Del Puente A, Scarpa R (2015) Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. Expert Opin Biol Ther 15(1):1–2. https://doi.org/10.1517/14712598.2015.973398
doi: 10.1517/14712598.2015.973398
pubmed: 25323456
Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A, Scarpa R, Costa L (2016) Emerging drugs for psoriatic arthritis. Exp Opin Emerg Drugs 21(1):69–79. https://doi.org/10.1517/14728214.2016.1146679
doi: 10.1517/14728214.2016.1146679
Atzeni F, Costa L, Caso F, Scarpa R, Sarzi-Puttini P (2015) Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis. J Rheumatol Suppl 93:79–81. https://doi.org/10.3899/jrheum.150643
doi: 10.3899/jrheum.150643
pubmed: 26523064
Scarpa R, Costa L, Atteno M, Del Puente A, Caso F, Moll JM (2013) Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother 14(17):2311–2313. https://doi.org/10.1517/14656566.2013.840292
doi: 10.1517/14656566.2013.840292
pubmed: 24067053
Costa L, Del Puente A, Peluso R, Tasso M, Caso P, Chimenti MS, Sabbatino V, Girolimetto N, Benigno C, Bertolini N, Del Puente A, Perricone R, Scarpa R, Caso F (2017) Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother 18(15):1557–1567. https://doi.org/10.1080/14656566.2017.1378343
doi: 10.1080/14656566.2017.1378343
pubmed: 28891341
Chiricozzi A, Saraceno R, Novelli L, Fida M, Caso F, Scarpa R, Costa L, Perricone R, Romanelli M, Chimenti S, Chimenti MS (2016) Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015). Exp Opin Ther Pat 26(7):757–766. https://doi.org/10.1080/13543776.2016.1192129
doi: 10.1080/13543776.2016.1192129
Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol (Hoboken, NJ) 68(5):1060–1071. https://doi.org/10.1002/art.39573
doi: 10.1002/art.39573
Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS (2016) Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol 12(12):743–750. https://doi.org/10.1038/nrrheum.2016.183
doi: 10.1038/nrrheum.2016.183
pubmed: 27829672
Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510. https://doi.org/10.1136/annrheumdis-2015-208337
doi: 10.1136/annrheumdis-2015-208337
pubmed: 26644232
Costa L, Lubrano E, Ramonda R, Chimenti MS, Vezzu M, Perrotta FM, Del Puente A, Peluso R, Bottiglieri P, Lorenzin M, Sunzini F, Darda MA, Fiocco U, Perricone R, Punzi L, Scarpa R, Caso F (2017) Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. Clin Rheumatol 36(8):1797–1802. https://doi.org/10.1007/s10067-017-3697-3
doi: 10.1007/s10067-017-3697-3
pubmed: 28589323
Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, Lubrano E, Peluso R, Caso P, Galeazzi M, Punzi L, Scarpa R, Costa L (2015) Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther 15(5):641–650. https://doi.org/10.1517/14712598.2015.1011616
doi: 10.1517/14712598.2015.1011616
pubmed: 25652590
Costa L, Caso F, Del Puente A, Di Minno MN, Peluso R, Scarpa R (2016) Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study. J Rheumatol 43(12):2149–2154. https://doi.org/10.3899/jrheum.160542
doi: 10.3899/jrheum.160542
pubmed: 27633825
Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, Bocchino ML, Sanduzzi A, Scarpa R (2014) The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 33(4):543–547. https://doi.org/10.1007/s10067-014-2536-z
doi: 10.1007/s10067-014-2536-z
pubmed: 24554385
pmcid: 3962579
Napolitano M, Costa L, Caso F, Megna M, Scarpa R, Balato N, Ayala F, Balato A (2017) Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clin Rheumatol 36(7):1589–1593. https://doi.org/10.1007/s10067-017-3700-z
doi: 10.1007/s10067-017-3700-z
pubmed: 28567556
Chimenti MS, Ortolan A, Lorenzin M, Triggianese P, Talamonti M, Costa L, Caso F, Favero M, Teoli M, Galluzzo M, Scarpa R, Punzi L, Perricone R, Ramonda R (2018) Effectiveness and safety of ustekinumab in naive or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol 37(2):397–405. https://doi.org/10.1007/s10067-017-3953-6
doi: 10.1007/s10067-017-3953-6
pubmed: 29302829
Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, Bottiglieri P, Scarpa R, Caso F (2017) Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R&D 17(4):509–522. https://doi.org/10.1007/s40268-017-0215-7
doi: 10.1007/s40268-017-0215-7
Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence 12:1483–1503. https://doi.org/10.2147/PPA.S167508
doi: 10.2147/PPA.S167508
pubmed: 30174415
pmcid: 6110273
Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD open 1(1):e000181–e000181. https://doi.org/10.1136/rmdopen-2015-000181
doi: 10.1136/rmdopen-2015-000181
pubmed: 26819748
pmcid: 4716450
Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, Punzi L, Scarpa R, Spadaro A, Matucci-Cerinic M, Olivieri I (2011) Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 29(3 Suppl 66):S28–S41
pubmed: 21906425
Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53. https://doi.org/10.1136/ard.2008.102053
doi: 10.1136/ard.2008.102053
pubmed: 19147615
Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, Martin-Domenech R, Del Pino-Montes J, Manrique S, Castro-Villegas MC, Ruiz-Montesinos D, Sanchez-Alonso F, Diaz-Gonzalez F, Cea-Calvo L, Gomez-Reino JJ (2019) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int 39(3):509–515. https://doi.org/10.1007/s00296-018-4177-z
doi: 10.1007/s00296-018-4177-z
pubmed: 30353269
Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL (2017) Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol 36(8):1747–1755. https://doi.org/10.1007/s10067-017-3712-8
doi: 10.1007/s10067-017-3712-8
pubmed: 28597133
Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli S, Galeazzi M (2014) Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediat Inflamm 2014:862969. https://doi.org/10.1155/2014/862969
doi: 10.1155/2014/862969
Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, Fusaro E, Parisi S, Massarotti M, Marchesoni A, Meroni PL (2017) Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res (Hoboken) 69(6):867–874. https://doi.org/10.1002/acr.23090
doi: 10.1002/acr.23090